Patents by Inventor Celia Patricia Shorrock

Celia Patricia Shorrock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180230209
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: November 27, 2017
    Publication date: August 16, 2018
    Inventors: Phillip David MONK, Lutz JERMUTUS, Celia Patricia SHORROCK, Ralph Raymond MINTER
  • Patent number: 9856317
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: January 2, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Publication number: 20160280779
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 29, 2016
    Inventors: Phillip David MONK, Lutz JERMUTUS, Celia Patricia SHORROCK, Ralph Raymond MINTER
  • Patent number: 9315575
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: April 19, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Publication number: 20130101595
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: September 5, 2012
    Publication date: April 25, 2013
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Publication number: 20120052060
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 1, 2012
    Applicant: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Patent number: 7947273
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: May 24, 2011
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Patent number: 7935343
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: May 3, 2011
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Ulrich Jochen Jermutus, Ralph Raymond Minter, Celia Patricia Shorrock
  • Publication number: 20110008357
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: May 24, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Patent number: 7829090
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: November 9, 2010
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Patent number: 7767207
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: August 3, 2010
    Assignee: Abbott Laboratories
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Publication number: 20100104563
    Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
    Type: Application
    Filed: February 9, 2001
    Publication date: April 29, 2010
    Inventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
  • Publication number: 20090123478
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 14, 2009
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter